BTN3A2: A Protein with Potential Drug and Biomarker Uses (G11118)

Target Name: BTN3A2

NCBI ID: G11118

BTN3A2

BTN3A2: A Protein with Potential Drug and Biomarker Uses

BTN3A2, also known as Butyrophilin subfamily 3 member A2, is a protein that is expressed in various tissues throughout the body, including muscle, heart, and brain. It plays a critical role in the regulation of muscle contractions and has been linked to a number of diseases, including muscular dystrophy, myopathies, and neurodegenerative disorders.

In recent years, researchers have been increasingly interested in investigating the potential drug targets for BTN3A2. This is because the protein has been shown to play a role in a number of diseases and conditions, including muscle weakness, muscle dysfunction, and neurodegenerative disorders. As a result, BTN3A2 has become a focus of research in the pharmaceutical industry, with several companies currently conducting clinical trials to investigate the potential uses of BTN3A2 as a drug target.

One of the key challenges in investigating BTN3A2 as a drug target is its complex structure. BTN3A2 is a 194-amino acid protein with four distinct subunits. It consists of a N-terminus, a catalytic center, a transmembrane region, and an C-terminus. The N-terminus of BTN3A2 contains a putative N-methyl group, which is thought to play a role in its stability and function. The catalytic center is located in the middle of the protein and is responsible for the catalytic activity of BTN3A2. The transmembrane region is located at the end of the protein and is responsible for its ability to interact with other proteins and molecules. The C-terminus is located at the opposite end of the protein and is responsible for its ability to interact with the extracellular matrix.

In addition to its complex structure, BTN3A2 is also known for its ability to interact with a variety of different proteins and molecules. This has led to the idea that it may be a useful drug target for a number of different diseases. For example, BTN3A2 has been shown to interact with the protein known as FBN1, which is involved in the regulation of blood clotting. This suggests that BTN3A2 may be a useful drug target for diseases that are characterized by inflammation or clotting problems.

Another potential drug target for BTN3A2 is its role in the regulation of muscle contractions. BTN3A2 is known to play a role in the regulation of muscle cell signaling, which is important for muscle function and growth. This suggests that BTN3A2 may be a useful drug target for diseases that are characterized by muscle weakness or dysfunction.

In addition to its potential as a drug target, BTN3A2 is also being investigated as a biomarker for a number of different diseases. This is because the protein is often expressed at higher levels in diseases than in healthy tissues, which makes it a potential source of diagnostic information. For example, BTN3A2 has been shown to be expressed at higher levels in muscles than in other tissues, which may be a useful indicator of muscle damage or disease.

Overall, BTN3A2 is a protein that has the potential to be a drug target or biomarker for a number of different diseases. As research continues to investigate its role in these areas, it is likely that we will learn more about its potential applications in the future.

Protein Name: Butyrophilin Subfamily 3 Member A2

Functions: Plays a role in T-cell responses in the adaptive immune response. Inhibits the release of IFNG from activated T-cells

The "BTN3A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTN3A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets